What We Learned about COVID-19 So Far? Notes from Underground

Basit Öğe Kaydı
dc.authorid
dc.contributor.authorAkyıl, Fatma Tokgöz
dc.contributor.authorKaradoğan, Dilek
dc.contributor.authorGündüz, Canan
dc.contributor.authorYüksel, Aycan
dc.contributor.authorArıkan, Hüseyin
dc.contributor.authorEyüboğlu, Tuğba Şişmanlar
dc.contributor.authorAkgün, Metin
dc.date.accessioned2021-12-01T18:21:38Z
dc.date.available2021-12-01T18:21:38Z
dc.date.issued2020
dc.department[Belirlenecek]en_US
dc.description.abstractThe novel coronavirus pandemic poses a major global threat to public health. Our knowledge concerning every aspect of COVID-19is evolving rapidly, given the increasing data from all over the world. In this narrative review, the Turkish Thoracic Society Early CareerTaskforce members aimed to provide a summary on recent literature regarding epidemiology, clinical findings, diagnosis, treatment,prevention, and control of COVID-19. Studies revealed that the genetic sequence of the novel coronavirus showed significant identityto SARS-CoV and MERS-CoV. Angiotensin-converting enzyme 2 receptor is an important target of the SARS-CoV-2 while entering anorganism. Smokers were more likely to develop the disease and have a higher risk for ICU admission. The mean incubation periodwas 6.4 days, whereas asymptomatic transmission was reported up to 25 days after infection. Fever and cough were the most commonsymptoms, and cardiovascular diseases and hypertension were reported to be the most common comorbidities among patients. Clinicalmanifestations range from asymptomatic and mild disease to severe acute respiratory distress syndrome. Several patients showed typicalsymptoms and radiological changes with negative RT-PCR but positive IgG and IgM antibodies. Although radiological findings may vary,bilateral, peripherally distributed, ground-glass opacities were typical of COVID-19. Poor prognosis was associated with older age, higherSequential Organ Failure Assessment score, and high D-dimer level. Chloroquine was found to be effective in reducing viral replicationin vitro. Likewise, protease inhibitors, including lopinavir/ritonavir, favipiravir, and nucleoside analogue remdesivir were proposed to bethe potential drug candidates in COVID-19 management. Despite these efforts, we still have much to learn regarding the transmission,treatment, and prevention of COVID-19en_US
dc.identifier.doi10.5152/TurkThoracJ.2020.20052
dc.identifier.endpage192en_US
dc.identifier.issn2149-2530
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85086933171en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage185en_US
dc.identifier.urihttps://doi.org/10.5152/TurkThoracJ.2020.20052
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TXpjd056VTVPUT09
dc.identifier.urihttps://hdl.handle.net/20.500.12684/9229
dc.identifier.volume21en_US
dc.identifier.wosWOS:000540904400009en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Thoracic Journalen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keywords]en_US
dc.titleWhat We Learned about COVID-19 So Far? Notes from Undergrounden_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
9229.pdf
Boyut:
575.93 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu